| 5LMB | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | 6ZF, GOL, PTR | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors., Garton NS, Barker MD, Davis RP, Douault C, Hooper-Greenhill E, Jones E, Lewis HD, Liddle J, Lugo D, McCleary S, Preston AG, Ramirez-Molina C, Neu M, Shipley TJ, Somers DO, Watson RJ, Wilson DM, Bioorg Med Chem Lett. 2016 Oct 1;26(19):4606-12. doi: 10.1016/j.bmcl.2016.08.070., Epub 2016 Aug 23. PMID:27578246 | ||||||||||||||
| Data retrieval |
![]() |
| View 5LMB in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |